Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Sicurezza del condizionamento mieloablativo, Orca-T e cellule T allogeniche derivate da donatori CD19/CD22-CAR (recettore dell'antigene chimerico) negli adulti con leucemia linfoblastica acuta a cellule B (ALL)

1 settembre 2026 aggiornato da: Melody Smith

Sperimentazione di fase I per valutare la sicurezza del condizionamento mieloablativo, Orca-T e cellule T allogeniche, derivate da donatori CD19/CD22-CAR (recettore dell'antigene chimerico) in adulti con leucemia linfoblastica acuta a cellule B (ALL)

To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD or graft failure.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

22

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Palo Alto, California, Stati Uniti, 94305
        • Stanford Cancer Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Patient Inclusion Criteria:

  • Subjects in CR must have a history of chemotherapy refractory disease defined as progression or stable disease after one line of chemotherapy, or relapsed disease after achieving prior CR OR must have other high risk ALL features including: CRLF2 rearrangement, Ph-like phenotype, MLL/KMT2a rearrangement, or hypodiploid karyotype.

  • Subjects with persistent or relapsed minimal residual disease (MRD) (by flow cytometry, PCR, FISH, or next generation sequencing) require verification of MRD in the peripheral blood or bone marrow on two occasions at least 2 weeks apart.

  • Subjects with active ALL (defined as >=5% bone marrow blasts, circulating blasts, or extramedullary disease) are eligible.

  • Age ≥ 18 and ≤ 65 years (i.e., from age 18 to < 66 years old) at the time of enrollment

  • Eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2; or Karnofsky ≥ 60%

  • CD19 expression is required any time since diagnosis. CD19 expression may be detected by immunohistochemistry or by flow cytometry. The choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each subject. In general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples. Patients receiving prior CD19 CAR T cell or blinatumomab are eligible if there is no documented history of CD19 negativity on the malignant cells.

  • Subjects must have an HLA matched related donor willing to undergo unstimulated apheresis for T cell collection for CAR T cell generation followed by GCSF mobilized apheresis for HSC/Treg graft.

  • Matched related donor who is an 8/8 match for HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods

  • Subjects must have adequate organ function measured by:

    • Cardiac: Cardiac ejection fraction at rest ≥ 45%
    • Hepatic:
    • Total bilirubin < 2 times upper limit of normal (ULN) (patients with Gilbert's syndrome may be included where hemolysis has been excluded and with approval of the study PI)
    • ALT/AST <= 3 times ULN
    • Renal: Calculated creatinine clearance ≥ 50 mL/min or serum creatinine < 2.0 mg/dL
    • Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO) (adjusted for hemoglobin) ≥ 50%
    • CNS: Subjects with CNS involvement are eligible as long as there are no overt signs or symptoms that in the evaluation of the investigator would mask or interfere with the neurological assessment of toxicity.
  • Negative serum or urine beta-HCG test in females of childbearing potential within 3 weeks of registration

  • Subjects of childbearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study and for twelve (12) months after receiving the preparative conditioning regimen.

  • Must be able to give informed consent. Legal authorized representative (LAR) is permitted if subject is cognitively able to provide verbal assent.

Donor Inclusion Criteria

  • Age ≥ 18 and ≤ 75 years at time of enrollment

  • Karnofsky performance status of ≥ 70% defined by institutional standards

  • Willing to donate for two separate apheresis collections (T cells and PBSC)

  • Matched related donor who is an 8/8 match for HLA-A, -B, -C, and -DRB1, all typed using DNA-based high-resolution methods

  • Negative serum or urine beta-HCG test in females of childbearing potential within 2 weeks of first apheresis

  • Seronegative for HIV-1 RNA PCR; HIV 1 and HIV 2 Ab (antibody); HTLV-1 and HTLV-2 Ab; PCR negative or sAg (surface antigen) negative for hepatitis B; negative for the Treponema pallidum antibody Syphilis screen; and negative for HIV-1 and hepatitis C by nucleic acid testing (NAT) within 40 days of donor apheresis procedures.

  • In the case that T pallidum antibody tests are positive, donors must:

    • Be evaluated and show no evidence of syphilis infection of any stage by physical exam and history
    • Have completed effective antibiotic therapy to treat syphilis
    • Have a documented negative non-treponemal test (such as RPR) or in the case of a positive non-treponemal test must be evaluated by an infectious disease expert to evaluate for alternative causes of test positivity and confirm no evidence of active syphilitic disease

Patient Exclusion Criteria:

  • History of other malignancy unless disease free for at least 3 years. At the discretion of the Principal Investigator, subjects in remission for 1-2 years prior to enrollment may be deemed eligible after considering the nature of other malignancy, likelihood of recurrence for one year following therapy, and impact of prior treatment on risk of CD19/CD22-CAR T cells and Treg graft. Subjects in remission <1 year are not eligible. The following exceptions apply:

    • Nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) is eligible.
    • Hormonal therapy in subjects in remission >1 year will be allowed.
  • Patients who have undergone a prior allogeneic or autologous stem cell transplant.

  • Recipient positive anti-donor HLA antibodies against a mismatched allele in the selected donor determined by either:

    • a positive crossmatch test of any titer (by complement-dependent cytotoxicity or flow cytometric testing), or
    • the presence of anti-donor HLA antibody to any of the following HLA loci: HLA-A, -B, -C, -DRB1, -DQB1, -DQA1, -DPB1, or -DPA1, with mean fluorescence intensity (MFI) >1000 by solid phase immunoassay
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.

  • Known history of infection with any of the following:

  • HIV

  • Hepatitis B (HBsAg positive) **

  • Hepatitis C virus (anti HCV positive) **

    ** A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.

  • Currently receiving corticosteroids or other immunosuppressive therapy. Topical corticosteroids or oral systemic corticosteroid doses less than or equal to 10 mg/day are allowed.

  • Planned pharmaceutical in vivo or ex vivo T cell depletion, e.g., post-transplant cyclophosphamide (Cy), peri-transplant anti-thymocyte globulin (ATG), or alemtuzumab. For patients that have previously been exposed to a T cell-depleting agent, a 5-half-life washout of the agent must occur prior to planned Transplant Day 0.

  • Hyperleukocytosis (≥ 50,000 blasts/μL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy.

  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.

  • Pregnant or breast feeding

  • Patients with known autoimmune disease requiring the use of systemic immunosuppressive therapy within the last year

  • Presence of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement that in the judgment of the investigator may impair the ability to evaluate neurotoxicity.

  • Any medical condition that in the judgement of the investigator is likely to interfere with assessment of safety or efficacy of study treatment

Donor Exclusion Criteria

  • Evidence of active infection

  • Seropositive for HIV-1 or -2, HTLV-1 or -2

  • Positive PCR test results indicating acute or chronic HBV infection. Patients with isolated HBV core antibody positivity will not be excluded. Donors whose HBV infection status cannot be determined conclusively by serologic test results (www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf) must be negative for HBV by PCR to be eligible for study participation.

  • Potential for Zika virus infection as defined as any of the following:

    • Medical diagnosis of Zika virus infection in the past 6 months
    • Residence in, or travel to, an area with active Zika virus transmission within the past 6 months.
    • Unprotected sex within the past 6 months with a person who is known to have either of the risk factors listed above (donor exclusion criterion 5.a or 5.b)
  • Donors determined to be ineligible based on the results of Zika virus screening may be determined to be eligible if:

    o The donor has no signs or symptoms consistent with active Zika virus infection and

    o Either of the following is true: i. The donor is a first-degree or second-degree blood relative of the recipient ii. Urgent medical need, meaning no comparable human cell product is available and the recipient is likely to suffer death or serious morbidity without the human cell product, as attested by the Investigator.

  • Pregnant or breastfeeding female

  • Medical, physical, or psychological reason that would place the donor at increased risk for complications from growth factor or leukapheresis.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dose escalation

Bayesian dose escalation design for the dosing of the donor CD19/CD22-CAR T cells

CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration

Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Patients Who Received Donor CD19/CD22-CAR T Cells
Lasso di tempo: 42 days

Will be measured by the ability to manufacture donor CD19/CD22-CAR T cells that meet established release specifications

42 days
Assessment of the Donors Safety CD19/CD22-CAR T Cells Plus the Orca-T Graft
Lasso di tempo: 42 days

Safety of the donor CD19/CD22-CAR T cells plus the Orca-T graft will be assessed by the incidence of engraftment without Grade III to IV acute GVHD

42 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cumulative Incidence of Disease Progression
Lasso di tempo: 1 year

Measure by the cumulative incidence of relapse or progression of disease as well as non-relapse mortality (NRM) following donor CD19/CD22-CAR T cells plus Orca-T infusion

1 year
Frequency of Secondary Graft Failure
Lasso di tempo: 1 year

Assessment of the rate of secondary graft failure following donor CD19/CD22-CAR T cells plus Orca-T infusion

1 year
Progression-free Survival
Lasso di tempo: 1 year

progression-free survival following a donor CD19/CD22-CAR T cell infusion plus Orca-T infusion

1 year
Overall Survival
Lasso di tempo: 1 year

overall survival following a donor CD19/CD22-CAR T cell infusion plus Orca-T infusion

1 year
Infectious Disease Complication
Lasso di tempo: 1 year

Evaluate the incidence of greater than Grade 3 infectious disease complications

1 year

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Lori Muffly, MD, Stanford University

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

18 agosto 2022

Completamento primario (Effettivo)

18 giugno 2025

Completamento dello studio (Stimato)

1 dicembre 2045

Date di iscrizione allo studio

Primo inviato

17 agosto 2022

Primo inviato che soddisfa i criteri di controllo qualità

17 agosto 2022

Primo Inserito (Effettivo)

19 agosto 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi